Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Improve Your Stream Voyage with Remarkable Trips and Exercises - 2UK to hold fresh pork, other affected Spanish products at border amid African swine fever outbreak
- 3Video of clashes over purported conscription orders misrepresented as anti-war protest in Israel
- 45 Morning Schedules That Stimulate Your Day
- 5NASA begins the countdown for humanity's first launch to the moon in 53 years
- Could it be said that you are As yet Utilizing Old Tires? at These 6 Tire Brands
- Monetary Wellness: Planning Tips for Independence from the rat race
- Figure out How to Involve a Brain science Certification in Showcasing
- Surge of off‑lease electric vehicles expected to drive down used EV prices
- Scientists captured female sperm whales on video working together during a birth to protect the calf
- US FDA unveils new pathway to approve personalized therapies
- Foreign journalist kidnapped in Iraq: Interior Ministry
- I tried a macho, creatine-loaded cereal “for men.” Did I mention I'm a woman?
- What's The Friendliest City In The United Kingdom?
